Skip to main content
The Journal of Biological Chemistry logoLink to The Journal of Biological Chemistry
. 2017 Mar 10;292(10):4359. doi: 10.1074/jbc.A117.553818

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Kush Dalal, Mani Roshan-Moniri, Aishwariya Sharma, Huifang Li, Fuqiang Ban, Mohamed D Hassona, Michael Hsing, Kriti Singh, Eric LeBlanc, Scott Dehm, Emma S Tomlinson Guns, Artem Cherkasov, Paul S Rennie
PMCID: PMC5354479  PMID: 28283588

VOLUME 289 (2014) PAGES 26417–26429

PAGE 26421:

Based on misinterpretation of the NMR spectra provided by our chemical vendor, the structure of VPC-14449 should be corrected. VPC-14449 (4-(4-(4,5-bromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine) should be replaced with VPC-14449 (4-(4-(2,4-dibromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine). In Fig. 1A, the graphical representation of VPC-14449 should be changed to the correct structure. Our industry partner synthesized the published VPC-14449 structure (4,5-bromo) and noticed that its NMR spectrum was different from that of our VPC-14449 stock synthesized by our chemical vendor. Upon synthesizing the correct structure (2,4-bromo), it was found that the NMR spectrum of the newly synthesized 2,4-bromo compound superimposed with the NMR spectrum of the compound supplied by our chemical vendor, establishing that the original compound used in this article was the 2,4-bromo version. In conclusion, our stock of VPC-14449 supplied by our chemical vendor and used in this article is (4-(4-(2,4-dibromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine). This error does not affect the results or conclusions of this work, as we simply reported the incorrect structure of our compound.

graphic file with name zbc0091763700001.jpg


Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES